Treatment of GLP-1 for Diabetic Bariatric Patients

Part of paid clinical trials in Danville, Pennsylvania.

Sponsor
Geisinger Clinic
Study ID
NCT04624672
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide (1 Mg Dose) — DRUG
    Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
  • Placebo — DRUG
    Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery

Study Details

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

Key Dates

Start date
Aug 25, 2021
Status verified
Oct 2023
Primary completion
Jul 18, 2022
Completion
Aug 17, 2022

Study Design

Enrollment
3 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Control Arm
    Once weekly injection of placebo 4-6 months at prescribed dose
  • Active Comparator: Test Arm
    Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose

Primary Outcome Measure

RATE OF PARTIAL REMISSION OF DIABETES [ Time Frame: 11 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Geisinger Medical CenterDanvillePennsylvania17822-

Find similar trials in Danville, PA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Geisinger Medical Center· Danville, PA

Related Studies